The Global Allergy Immunotherapy Market is likely to gain impetus from the growing advancements in medicines and treatments. Fortune Business Insights, in a report, titled “Allergy Immunotherapy Market Size, Share and Global Trend by Treatment (Subcutaneous Immunotherapy, Sublingual Immunotherapy), by Allergy (Allergic Rhinitis, Asthma, Food Allergy, Drug Allergy, Others), by Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Drug Stores, Online Pharmacies), and Geography Forecast till 2026,” states that emergence of new immunotherapy drugs, increasing industrialization, and a rise in population across the globe are the major factors contributing to the growth of the global allergy immunotherapy market. Fortune Business Insights predicts that the global allergy market is anticipated to grow due to the regulatory approvals such as oral dissolvable tablets.
Browse Complete Report Details at https://www.fortunebusinessinsights.com/industry-reports/allergy-immunotherapy-market-100727
Some of the major companies that are present in the Global Allergy Immunotherapy Market are
- Merck KGaA
- Stallergenes Greer
- Aimmune Therapeutics
- DBV Technologies
- Allergy Therapeutics
- HAL Allergy B.V.
- Biomay AG
- Anergis, and other prominent companies.
Increasing Prevalence of Diabetes, Hypertension, and Other Chronic Diseases to Propel the Global Market
The report suggests that the increasing adoption of immunotherapy has resulted in a rise in the demands from the emerging economies. There has also been an increase in the awareness programs about allergy treatments. Rising prevalence of chronic diseases, namely, asthma, diabetes, hypertension, and allergy are boosting the growth of the global allergy immunotherapy market. Numerous key market players are focusing more on strategic collaboration with independent research centres and hospitals. This is undertaken to develop innovative and advanced methods of treatment. Persistent research and developments activities, clinical trials, and approvals are impacting the global allergy immunotherapy market positively. Clinicians and medical professionals are adopting this form at a rapid rate due to tremendous success in treatment procedures.
Increase in the Allergic Patient Pool is Expected to Favor Growth in Asia Pacific
The global allergy immunotherapy market is geographically divided into Latin America, Europe, the Middle East and Africa, North America, and Asia Pacific. Currently, North America and Europe are two of the most dominating markets of allergy immunotherapy. Fortune Business Insights states that these two regions will remain in their positions and will hold a significant portion of the market during the forecast period. Europe is expected to show considerable growth and procure the second largest market share in terms of revenue. This is because of the increasing cases of allergies, rise in the awareness of this form of treatment, and medical reimbursement policies. Also, companies are investing huge amount of money on grants and research activities. The market in Asia Pacific, on the other hand, is growing at a very rapid rate. A rise in the allergic patient pool in this region is anticipated to boost growth of the market during the forecast period.
Sandoz Inc., Aimmune Therapeutics, and Other Key Players Focus on Innovative Product Launches to Strengthen Position in Market
Sandoz Inc., global leader in generic and biosimilar medicines, based in the U.S., announced the launch of SYMJEPI (epinephrine) 0.3 mg injection in January 2019. The injection will be used to treat allergic reactions (Type 1), such as anaphylaxis to stinging and insect biting. The medicine is single dosed, cost effective, and is pre-filled in the syringe. The injection is intended for immediate application in patients who are prone to allergic reactions, including people who have a history of anaphylactic reactions.
Aimmune Therapeutics, a developer of medicines to protect children with food allergies, headquartered in the U.S., announced its phase III trial results for AR101 in June 2018. The AR101 is an oral immunotherapy drug that is used to treat peanut allergies in children who belong to the age group of 1 to 3 years. The drug has met all the requirements as per the rules of the FDA. Aimmune Therapeutics is pleased with the results of the trial which declares that the drug has effectively improved the conditions of patients to tolerate the 1,000-mg dose of peanut protein. In June 2018, Torii Pharmaceutical Co., Ltd., a pharmaceutical company based in Japan, launched CEDARCURE, a cedar sublingual allergy immunotherapy tablet in June 2018. The tablets have been approved for the treatment of Japanese cedar pollinosis in adults and children.
View Related Report at
Fortune Business Insights offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.
Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
At Fortune Business Insights we aim at highlighting the most lucrative growth opportunities for our clients. We therefore offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.